Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 3Active not recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Hepatitis, Chronic 1Hepatitis C 1Glioblastoma 1Carcinoma, Hepatocellular 1BRCA1/2 Mutation 1

Interventions

pembrolizumab 86Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27atezolizumab 26Paclitaxel 26Ipilimumab 26Radiation 22Dexamethasone 22Cisplatin 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15palbociclib 14ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × rocakinogene sifuplasmid × Clear all
NCT04015700 2026-05-07

Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Washington University School of Medicine

Phase 1 Active not recruiting
9 enrolled 14 charts
CNS

Glioblastoma

NCT02772003 2026-04-13

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

National Cancer Institute (NCI)

Phase 1 Active not recruiting
33 enrolled
Gastrointestinal

Hepatitis, Chronic, Hepatitis C, Carcinoma, Hepatocellular

NCT04367675 2026-02-23

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Abramson Cancer Center at Penn Medicine

Phase 1 Active not recruiting
44 enrolled

BRCA1/2 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡